Acuitas touts lipid-nanoparticle delivery of mRNA vaccine for Zika

Acuitas Therapeutics touted preliminary data that evaluated its messenger RNA vaccine for the Zika virus. The company uses a lipid-nanoparticle delivery system to introduce its mRNA vaccine into cells.

The team’s work, which was published in Nature, showed that a single low-dose immunization with its vaccine triggered an immune response in animals and protected them from infection at 2 weeks, 5 weeks and 5 months post-vaccination.

Messenger RNA carries genetic information to code for specific proteins. Vancouver-based Acuitas introduces synthetic mRNA into a cell using its lipid-nanoparticle carriers to instruct the cell to produce a therapeutic protein.

Get the full story at our sister site, Drug Delivery Business News.

The post Acuitas touts lipid-nanoparticle delivery of mRNA vaccine for Zika appeared first on MassDevice.

from MassDevice http://ift.tt/2kxf5eK